Epcoritamab is a type of immunotherapy known as a bispecific antibody. It is designed to connect two types of cells in your body: T-cells (a type of immune cell) and B-cells (which can become cancerous in certain blood cancers). Epcoritamab binds to the CD3 receptor on T-cells and the CD20 receptor on B-cells, including lymphoma cells. By bringing these cells together, epcoritamab activates the T-cells to attack and destroy the cancerous B-cells.

This targeted approach helps your immune system recognize and kill lymphoma cells that might otherwise evade detection. Epcoritamab has been shown to reduce the number of circulating B-cells to undetectable levels in most patients, and it can cause a temporary increase in certain immune system proteins (cytokines) as your body responds to the treatment.

epcoritamab

Common brand names

Approved use in